Facts & figures

As of:  January, 2019

1) primarily from public funds (EU, Federal Government, State Government); according to Campus Buch: total funding since 1992, incl. BIMSB
2) primarily from own ressources, since 2001
3) primarily from own ressources
4) since 2009
5) since 2006
6) since 2002

Research Institutions of Campus Berlin-Buch
Employees (total)

2,151
 
of these:    
Max Delbrück Center for Molecular Medicine (MDC): 1,646  
Leibniz Institute of Molecular Pharmacology (FMP): 303  
Klinische Forschung Charité Campus Buch: 202  
     
Budget and third-party grants (total)1 EUR 192 million  
Max Delbrück Center for Molecular Medicine (MDC): EUR 147 million  
Leibniz Institute of Molecular Pharmacology (FMP): EUR 29 million  
Klinische Forschung Charité Campus Buch: EUR 16 million  
     
BiotechPark Berlin-Buch    
Number of companies: 62  
Employees: 800  
Annual revenue:
Percentage of third-party grants: 3,1%
EUR 220 million
 
 
     
Hospitals & Patient-Care Institutions    
Employees (total):
of these:
3,564  
HELIOS Klinikum Berlin-Buch: 2,700  
Evangelische Lungenklinik: 325  
Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik):
89
 
Patient-care institutions: 450  
Number of patient beds: 1,267  
Patients per year (inpatient and outpatient): 220,519  
     
Total investment volume
of these:
EUR 1.451 billion  
Infrastructure Campus Berlin-Buch1 EUR 624 million  
HELIOS Klinikum Berlin-Buch² EUR 336 million  
Evangelische Lungenklinik3 EUR 49 million  
Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik)1
EUR 39 million
 
LudwigPark 3 EUR 45 million  
Allées des Châteaux 3 EUR 23 million  
Widerker Vermögensverwaltung (Schlosspark-Passage) 3
EUR 29 million
 
Ludwig Hoffmann Quartier
EUR 152 million
 
Housing construction associations (HOWOGE 3,4, EWG 3,5, WBG 3,6 Hau+S 3,5 ) EUR 154 million  

News Buch Berlin

Starting up with highly promising immunotherapies

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse...

more ...

OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease

OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, today provided a positiv...

more ...

The thrill of science

Young students are fascinated by the experiments they can participate in at the Gläsernes Labor (Life Science Learning Lab). Thanks to a special fundraiser, socially disadvantaged children from the di...

more ...

Events Buch Berlin

09.10.2023, 09:00
Explore Precision Medicine Event im Futurium

Das Gläserne Labor beteiligt sich am 9. Oktober 2023 am Explore Precision Medicine Event im Futurium mit Workshops und Präsentationen.

more ...

This website is supported by: